Search

About two dozen MSK physicians and researchers shared their work at the world’s leading breast cancer conference, held annually in San Antonio.

… Friday, December 13, 2019 At the annual San Antonio Breast Cancer Symposium, MSK investigators presented the latest research on detection and screening methods for people at high risk; immunotherapy for breast cancer; and the underlying causes of resistance to targeted therapies, among other topics.

Memorial Sloan Kettering Cancer Center (MSK) issued the following statement regarding its financial results for the first two quarters of 2025:

… Friday, August 15, 2025 Memorial Sloan Kettering Cancer Center (MSK) issued the following statement regarding its financial results for the first two quarters of 2025:  MSK’s financial performance for the first half of 2025 resulted in a deficiency of operating revenues over expenses of $(113.2) million

Physicians and scientists from MSK will join oncology experts and members of the global cancer research community to present the latest advances in cancer during the 2022 ASCO Annual Meeting, June 3–7 in Chicago.

… Tuesday, May 31, 2022 Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3

The Howard Hughes Medical Institute (HHMI) announced that Memorial Sloan Kettering Cancer Center's Gerstner Sloan Kettering Graduate School of Biomedical Sciences is one of 23 research institutions to receive a grant as part of HHMI's Med into Grad Initiative.

… Monday, November 30, 2009 In November the Howard Hughes Medical Institute (HHMI) announced that Memorial Sloan Kettering Cancer Center’s Gerstner Sloan Kettering (GSK) Graduate School of Biomedical Sciences is one of 23 research institutions to receive a grant as part of HHMI’s Med into Grad Initiative

President Biden announced the appointment of seven distinguished clinicians and researchers to the National Cancer Advisory Board. Memorial Sloan Kettering Cancer Center’s Luis Alberto Diaz, Jr., MD, was among those appointed.

… Thursday, September 16, 2021 President Biden announced the appointment of seven distinguished clinicians and researchers to the National Cancer Advisory Board, which plays an important role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research

Researchers from Memorial Sloan Kettering Cancer Center (MSK) today published a seminal review of the rapidly evolving field of precision oncology, which allows doctors to recommend therapies based on a genetic understanding of a person’s cancer. Appearing in the special cancer-focused February 9 issue of Cell, the article — “Implementing Genome-Driven Oncology” — presents a critically self-reflective but solutions-focused perspective on this approach to cancer treatment.

… Thursday, February 9, 2017 Researchers from Memorial Sloan Kettering Cancer Center (MSK) today published a seminal review of the rapidly evolving field of precision oncology, which allows doctors to recommend therapies based on a genetic understanding of a person’s cancer. Appearing in the special cancer-focused

A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma. Investigators at Memorial Sloan Kettering Cancer Center and colleagues at other cancer centers have published their findings in the August 26 edition of the New England Journal of Medicine.

… Wednesday, August 25, 2010 A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma . Investigators at Memorial Sloan Kettering Cancer Center and colleagues

… Monday, November 9, 2020 Miriam Lorena Murray estaba en la mejor condición física de su vida cuando recibió una desgarradora noticia: su médico le diagnosticó, cáncer de mama. “Estaba en un estado dos ya pasando a un estado tres y sin ningún síntoma, viéndome espectacular”, contó Miriam Lorena de 50

Overall survival (OS) for patients with melanoma brain metastasis treated at Memorial Sloan Kettering Cancer Center has increased significantly over the past five years, up to 13 months, according to our research published recently in Cancer.

… Thursday, November 18, 2021 Overall survival (OS) for patients with melanoma brain metastasis treated at Memorial Sloan Kettering Cancer Center has increased significantly over the past five years, up to 13 months, according to our research published recently in Cancer .  (1) This increased OS duration

The first-ever clinical trial at MSK to evaluate a novel CAR T cell therapy for AML is showing promise.

… Friday, August 29, 2025 Chimeric antigen receptor (CAR) T cell therapies have changed the way that many blood cancers are treated. A type of immunotherapy, CAR T cells redirect a patient’s own immune system in the fight against cancer. Memorial Sloan Kettering Cancer Center (MSK) has been a leader in